This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
UK. Throughout the COVID-19 pandemic, Moderna worked with governments, healthcare professionals and other key stakeholders to help combat the virus and future pathogens. ... Moderna is collaborating with the National Institute for Health Research (NIHR)
In February 2021 Moderna announced it would update its booster candidates as the SARS-CoV-2 virus continued to evolve. ... Moderna plans to present the analysis and data to industry regulators in the coming weeks.
Moderna, a biotech company focused on developing messenger RNA (mRNA) therapeutics and vaccines, has won the Prix Galien UK award for best biotechnology product for its vaccine, Spikevax. ... Sharing his thoughts on the achievement, Darius Hughes,
Participants in the study included 70-year-olds and some under 70, and all received a dose of Pfizer or a half dose of Moderna around six months after having their ... of Moderna was slightly higher.".
spring of 2020 to help us get Moderna ready for commercialisation in record time. ... Moderna was an early-stage development, US-focused company when David joined us.
The fourth doses that were being considered are Pfizer’s Comirnaty and Moderna’s Spikevax – both mRNA COVID-19 vaccines.
More from news
Approximately 69 fully matching, plus 125 partially matching documents found.
In the US, both Pfizer and Moderna worked with community organisations to increase representation in the COVID-19 vaccine trials.
Until the likes of Pfizer, AstraZeneca and Moderna started to have their coronavirus vaccines approved, the companies behind the medicines were rarely recognised by the public. ... The pharmaceutical and biotech company Moderna was virtually unknown to
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for
At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna
More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.
Horning has also recently joined the board of directors at Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts.
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 ... With the emergency use authorisation and success of the Pfizer and
The following month, it happened again. Cambridge, Massachusetts-based Moderna said it had slowed enrolment in its phase 3 COVID-19 vaccine trial to ensure they were getting a representative population. ... Moderna effectively sacrificed potential sales,
15]. In fact, Moderna slowed down recruitment for its COVID-19 vaccine trial specifically to address a shortfall in recruitment from ethnically diverse populations for an illness that has been shown
Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. ... Since this initial announcement, other good news in vaccine development has followed, with companies and
In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 ... Since then, other good news has followed, with collaborations,
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...